Navigation Links
GFX: Wrinkle-Killer or Botox(R) Hit-Man?

NORTH DALLAS, Texas and PLANO, Texas, March 10 /PRNewswire/ -- Tired of frequent Botox injection visits? GFX might be the long-term wrinkle solution for you!

Newly-FDA approved GFX (Glabella Furrow Relaxation) recently arrived in North Texas and is already making waves -- radiofrequency waves, to be exact -- in select aesthetic centers and cosmetic surgery offices. GFX is a unique technological advancement in facial rejuvenation that offers long-term relaxation of overactive 'frown' muscles; a proposition likely to thrill many long-time Botox users, but one that targets the Botox(R) empire for a kill-shot where it would hurt the most ... right between the eyebrows.

Botox(R) muscle-relaxing injection results typically last from 3 to 4 months on average, while the results of one in-office GFX (sometimes called 'No-tox') treatment averages 18 months or longer. According to Jeffrey Adelglass, M.D., F.A.C.S., a popular North Dallas area cosmetic surgeon who has had plenty of experience working with a variety of cosmetic injectables, treatment of the glabella area alone constitutes approximately 65% -- the lion's share -- of his Botox injections. While his GFX patients might still receive periodic Botox(R) injections in other forehead areas (GFX is currently only FDA-approved for the glabella), sometimes keeping the glabella relaxed can, over time, soften wrinkles in other forehead areas, as well. An observed effect of the treatment has been that eyebrows gradually tend to become more elevated and horizontal forehead lines reduced, potentially eliminating the need for elective surgery or neurotoxin injections entirely for some aesthetic patients.

How does GFX work? This minimally-invasive, in-office procedure utilizes a specified dose of radiofrequency (RF) thermal energy, delivered through an insulated bipolar needle inserted near the eyebrows, on either side of the forehead. First, the doctor delivers a stimulating pulse through the needle tome and recovery.


Pamela Fox, Director of Communications, 972-620-3223

SOURCE SKINTASTIC Medical and Surgical Rejuvenation Center
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AAFPRS Speaks to the Safety of BOTOX(R) Cosmetic
2. American Society for Dermatologic Surgery Supports Current Labeling of Allergans Botox(R) Products
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... For the millions of ... Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic intermittent catheter. ... touch free catheter portfolio,” said Michael Gresavage, Vice President North America. "We designed ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... of Excellence (BHCOE) today announced that the organization has awarded Education and Developmental ... with a Distinguished Award. The award celebrates exceptional special needs providers that excel ...
(Date:12/1/2015)... ... 01, 2015 , ... McLean, VA., December 1, 2015 - ... per sprint agile development contract to support the National Geospatial-Intelligence Agency's (NGA) IT ... software engineering, infrastructure, as well as operations and sustainment support to the NGA’s ...
(Date:12/1/2015)... Auburn, CA (PRWEB) , ... December 01, 2015 ... ... software and clinical solutions for the care management and population health arenas, is ... on providing clinical and cost containment services, has successfully implemented the ACUITY Complete ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... has selected 10 semi-finalists to head to Las Vegas for CES 2016, the world’s ... including CEO of Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Dec. 1, 2015   Nottingham Spirk , ... announced the publication of a free whitepaper ... Medical Market". The whitepaper gives medical product companies, ... penetrating this lucrative segment. Nottingham Spirk ... to manage their own health, save money (i.e., ...
(Date:12/1/2015)... 2015 Array BioPharma Inc. (Nasdaq: ... Chief Executive Officer, Ron Squarer , ... Conference in New York.  The public is ... a webcast on the Array BioPharma website. ... --> , --> ...
(Date:12/1/2015)... , BANGALORE, India and ... N.V. (NASDAQ, TASE: MYL) today announced that it expects ... and for developing country markets funded by international donors, ... mg + Efavirenz 400 mg) for $99 per patient, ... Initiative (CHAI) to develop TLE400. The significantly reduced price ...
Breaking Medicine Technology: